Journal article icon

Journal article

STEP trial and HIV-1 vaccines inducing T-cell responses.

Abstract:

Recombinant, nonreplicating, human adenovirus serotype 5-vectored vaccine, known as MRKAd5, expressing three HIV-1 clade B-derived internal proteins when used in a homologous immunization regimen, did not decrease HIV-1 infection rate nor postinfection virus load in the first Phase IIb proof-of-concept trial. However, the vaccine did not reach the limits of vaccine T-cell induction and its design can be improved both from the point of the HIV-1-derived immunogens and their delivery. Therefore...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1586/14760584.7.3.303

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Journal:
Expert review of vaccines
Volume:
7
Issue:
3
Pages:
303-309
Publication date:
2008-04-05
DOI:
EISSN:
1744-8395
ISSN:
1476-0584
URN:
uuid:8f6de133-465f-4d7e-879a-99c0434fe999
Source identifiers:
67005
Local pid:
pubs:67005

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP